AlzeCure Pharma has announced a fully secured rights issue of SEK30.1m. The subscription price was set only slightly below the prevailing share price, which we consider a sign of relative strength in the current financing environment. Importantly, the transaction is 100% secured by two major shareholders, removing execution risk and underlining continued support from core owners. Overall, we view the rights issue as well executed and strategically sound.
LÄS MER
